JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Want to cut your energy bills? Here’s how five experts are doing it 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
LONDON, March 22, 2016 -- APCER Life Sciences, the truly global provider of safety, medical, regulatory, and technology services, will be a major participant in the Drug Information Association’s 28th Annual EuroMeeting, taking place April 6-8, 2016, in Hamburg, Germany. The company will host a presentation in the Innovation Theatre and have a large presence in the exhibit hall of the Congress Center Hamburg.
“We are excited that we have reached the point in our company’s growth where we can support the DIA EuroMeeting at a significant level,” said Michael Britt, APCER Europe’s business unit leader and Global Head of Quality and Compliance. “The European clients that we have been serving since our founding helped us define our value proposition and build our firm into the global presence it is today.”
APCER’s presentation in the Innovation Theatre is titled “Redefining PV: From Pharmacovigilance to Patient Voice and Product Value.” It will explore how pharmacovigilance, when practiced with consistency and integrated tightly with medical affairs, can yield a rich source of real-world patient data that quantifies product value and demonstrates a competitive advantage for partnering and out-licensing deals, formulary decisions, and reimbursement rates.
APCER Life Sciences is active in the Drug Information Association around the world. In addition to the EuroMeeting, the company will be speaking at the DIA Innovations in Pharmacovigilance meeting in Mumbai, India, May 13-14, and at the 52nd DIA Annual Meeting in Philadelphia, Pennsylvania, USA, June 27-30. APCER is also exhibiting at the DIA Medical Affairs and Scientific Communications Annual Forum in Orlando, Florida, USA, this week.
About APCER Life Sciences
APCER Life Sciences is committed to improving health in partnership with its clients. It brings together safety, medical, regulatory, and technology resources from around the world to ensure that patients receive the safest, most effective therapies possible.
To learn how APCER Life Sciences works together for better health, please follow the company on Twitter, LinkedIn, and Facebook; visit www.apcerls.com; then contact APCER at one of their global offices.
Contact: Jill Notte Director, Global Marketing +1-609-436-4714
